What's the status of apotex's ruxolitinib anda filing in us?

What is Apotex’s ruxolitinib ANDA and what does “status” usually mean?

An “ANDA” (Abbreviated New Drug Application) is how a generic company seeks FDA approval to market a drug that relies on an already-approved reference product’s safety and efficacy. For a ruxolitinib ANDA, the “status” could refer to where the filing is in the FDA review process (e.g., accepted, filed, received a complete response, or pending additional information) and whether a tentative approval or launch date is being discussed.

What we can confirm from the information provided

No details about Apotex’s specific ruxolitinib ANDA filing (case number, NDA/ANDA number, filing date, or current FDA action) were included in the information you provided. Without that information or a specific FDA application identifier to look up, I can’t state the current status accurately.

What you should check to get the exact current FDA status

To find the precise “status in the US,” you typically need one of these:
- The ANDA number for Apotex’s ruxolitinib application (e.g., “ANDA ###”).
- The FDA application page for that ANDA (which shows review and approval milestones).
- The FDA “Drugs@FDA” listing for the ANDA product (if approved or under review there).
- Any FDA correspondence or public patent exclusivity/listing information that affects approval timing.

If you share the ANDA number (or a link/screenshot to the FDA listing you’re looking at), I can help interpret what the current status means and what the next expected milestone is.

If your goal is launch timing: what usually controls it for ruxolitinib

Even when an ANDA is pending, ruxolitinib generic launch timing can be constrained by:
- Patent and exclusivity protections listed in FDA’s Orange Book for the reference product.
- Whether the ANDA received a “tentative approval” (which often triggers remaining litigation/patent-resolution timing).
- Any required labeling or manufacturing/CMC updates.

But the exact timing for Apotex depends on the specific ANDA posture and the listed protections for the relevant reference product.

Next step

Send the ANDA number (or the FDA link you’re using), and I’ll summarize the exact current status and what happens next based on that specific filing.